PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) reported a 22% confirmed response rate in a small Phase 1 trial of its experimental ovarian cancer treatment, CTIM-76, as…
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) reported a 22% confirmed response rate in a small Phase 1 trial of its experimental ovarian cancer treatment, CTIM-76, as the Philadelphia-based …
Source disclosure
This is a source-linked briefing. Read the original report from Mychesco .